What is William Blair’s Forecast for NuCana FY2024 Earnings?

NuCana plc (NASDAQ:NCNA) – Equities researchers at William Blair lifted their FY2024 EPS estimates for NuCana in a research note issued to investors on Monday, November 25th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($12.76) for the year, up from their previous estimate of ($15.75). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for NuCana’s current full-year earnings is ($13.20) per share. William Blair also issued estimates for NuCana’s Q4 2024 earnings at ($2.23) EPS, Q1 2025 earnings at ($2.23) EPS, Q2 2025 earnings at ($2.23) EPS, Q3 2025 earnings at ($2.23) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($9.57) EPS and FY2026 earnings at ($28.70) EPS.

Separately, Oppenheimer reduced their target price on NuCana from $150.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, September 3rd.

NuCana Price Performance

NuCana stock opened at $1.29 on Thursday. The firm has a market cap of $3.41 million, a PE ratio of -0.11 and a beta of 1.03. The stock’s fifty day moving average price is $1.86 and its two-hundred day moving average price is $3.08. NuCana has a one year low of $1.23 and a one year high of $19.41.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NuCana stock. Glass Jacobson Investment Advisors llc purchased a new stake in NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned about 0.57% of NuCana as of its most recent filing with the Securities and Exchange Commission. 44.00% of the stock is owned by institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.